Sugi Predict

Sugi Predict / Compounds / SCHEMBL3155202

SCHEMBL3155202

SCHEMBL3155202

O=c1c(I)c(CO)nc2ccccn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ GLA P06280 3/20 0.47
▸ GAA P10253 3/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MAPT P10636 3/20 0.45
▸ NPSR1 Q6W5P4 3/20 0.43
▸ HPGD P15428 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ ADORA3 P0DMS8 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ADORA1 P30542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3155115 0.84 KDM4E (0.47) KDM4EALDH1A1GLAGAASMN1; SMN2
SCHEMBL890574 0.81 KDM4E (0.47) KDM4EALDH1A1GLAGAASMN1; SMN2
SCHEMBL3146184 0.79 MAPK1 (0.43) KDM4EALDH1A1GLAGAASMN1; SMN2
SCHEMBL3155940 0.77 ENPP2 (0.54) KDM4EALDH1A1GLAGAASMN1; SMN2
SCHEMBL3143452 0.76 ALDH1A1 (0.41) KDM4EALDH1A1GAAHSD17B10CASP1
SCHEMBL8519386 0.76 KMT2A (0.53) KDM4EALDH1A1GLAGAASMN1; SMN2
SCHEMBL30402668 0.76 KDM4E (0.51) KDM4EALDH1A1GLAGAASMN1; SMN2
SCHEMBL296767 0.73 ALDH1A1 (0.53) KDM4EALDH1A1GLAGAAMAPT
SCHEMBL3755909 0.73 KDM4E (0.60) KDM4EALDH1A1GLAGAASMN1; SMN2
SCHEMBL2715301 0.73 MAPT (0.46) KDM4EALDH1A1GLAGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636225-B1 PYRIDINO 1,2-A PYRIMIDIN-4-ONE COMPOUNDS AS ANTICANCER AGENTS NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-02-24 — — EP disclosed
US-7662581-B1 Eg5 co-crystals NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-02-16 — — US disclosed
US-7662581-B1 Eg5 co-crystals NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-02-16 — — US disclosed
US-7662581-B1 Eg5 co-crystals NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-02-16 — — US disclosed
US-20090171082-A1 MITOTIC KINESIN INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-07-02 — — US disclosed
US-20090171082-A1 MITOTIC KINESIN INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-07-02 — — US disclosed
US-20090171082-A1 MITOTIC KINESIN INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-07-02 — — US disclosed
US-7504405-B2 Mitotic kinesin inhibitors NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-03-17 — — US disclosed
US-7504405-B2 Mitotic kinesin inhibitors NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-03-17 — — US disclosed
US-7504405-B2 Mitotic kinesin inhibitors NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-03-17 — — US disclosed
US-20080249112-A1 Mitotic Kinesin Inhibitors CHIRON CORPORATION (US) 2008-10-09 — — US disclosed
US-7326711-B2 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents CHIRON CORPORATION (US) 2008-02-05 — — US disclosed
US-7326711-B2 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents CHIRON CORPORATION (US) 2008-02-05 — — US disclosed
US-7326711-B2 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents CHIRON CORPORATION (US) 2008-02-05 — — US disclosed
EP-1732926-A1 MITOTIC KINESIN INHIBITORS CHIRON CORPORATION (US) 2006-12-20 — — EP disclosed
EP-1636225-A2 PYRIDINO 1,2-A PYRIMIDIN-4-ONE COMPOUNDS AS ANTICANCER AGENTS Chiron Corporation (US) 2006-03-22 — — EP disclosed
WO-2005100357-A1 MITOTIC KINESIN INHIBITORS CHIRON CORPORATION (US) 2005-10-27 — — WO disclosed
US-20050228002-A1 Mitotic kinesin inhibitors CHIRON CORPORATION (US) 2005-10-13 — — US disclosed
US-20050085490-A1 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents CHIRON CORPORATION 2005-04-21 — — US disclosed
WO-2004113335-A2 PYRIDINO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS AS ANTICANCER AGENTS CHIRON CORPORATION (US) 2004-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090171082-A1 MITOTIC KINESIN INHIBITORS KIF5B, KIF2C, KIFC1 KDM4E 818/4885ALDH1A1 2701/4885GLA 2860/4885
US-20050085490-A1 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents TYMP, DPYD, TK1 KDM4E 3300/4885ALDH1A1 290/4885GLA 1932/4885
US-20050228002-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIFC1 KDM4E 818/4885ALDH1A1 2701/4885GLA 2860/4885
US-20080249112-A1 Mitotic Kinesin Inhibitors KIF5B, KIF2C, KIFC1 KDM4E 810/4885ALDH1A1 2363/4885GLA 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.